One case of non-small cell lung adenocarcinoma patient developed severe liver injury (ALT 319.6 U·L^-1, AST 103.3 U·L^-1, ALP 586.8 U·L^-1, DBIL 104.0 μmol·L^-1, TBIL 172.3  μmol·L^-1, IBIL 68.3 μmol·L^-1), after multiple cycles of chemotherapy combined with camrelizumab. Subsequently, fever and jaundice on the face and sclera were noticed. Based on the previous medication, the RUCAM scale and the R value was used to evaluated the symptons, suggested a high likelihood of drug-induced cholestatic liver injury caused by camrelizumab. Clinical pharmacist proposed drug therapy recommendations for liver injury treatment and the selection of protective drugs. The physician adopted some of these therapeutic suggestions, and the patient was treated with methylprednisolone and hepatoprotective drugs. Although there was a temporary improvement in transaminase levels, bilirubin levels continued to rise. Later, the patient asked to discharge and passed away at home. Immune-related cholestatic liver injury caused by camrelizumab is insensitive to glucocorticoid therapy, clinicians should promptly consider adding immunosuppressants to enhance prognosis. Literature studies have shown that dual-molecule plasma adsorption system sequential plasma exchange has a certain therapeutic effect on immune-related cholestatic liver injury.

1.郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. [Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022[J]. Chinese Journal of Oncology, 2024, 46(3): 221-231.] DOI: 10.3760/cma.j.cn112152-20240119-00035.

2.国家药品不良反应监测中心. 药品不良反应术语使用指南 [S]. 2016: 68.

3.中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南（2023年版）[J]. 中华肝脏病杂志, 2023, 31(4): 355-384. [Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)[J]. Chinese Journal of Hepatology, 2023, 31(4): 355-384.] DOI: 10.3760/cma.j.cn501113-20230419-00176-1.

4.Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries[J]. J Clin Epidemiol, 1993, 46(11): 1323-1330. DOI: 10.1016/0895-4356(93)90101-6.

5.中国临床肿瘤学会. 免疫检查点抑制剂相关的毒性管理指南 [S]. 2023: 53.

6.Laura S, Nicholas C, Miranda P. Toxicities associated with check point inhibitiors-an overview[J]. Rheumatology (Oxford), 2019, 58 (suppl 7): vii7-vii16. DOI: 10.1093/rheumatology/kez418.

7.Peeraphatdit TB, Wang J, Odenwald MA, et al. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation[J]. Hepatology, 2020, 72(1): 315-329. DOI: 10.1002/hep.31227.

8.Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.

9.中国临床肿瘤学会. 抗肿瘤药物相关肝损伤诊疗指南[S]. 2024: 62-63.

10.中华医学会肝病学分会. 胆汁淤积性肝病管理指南（2021） [J]. 中华肝脏病杂志, 2022, 30(3): 253-263. [Chinese Society of Hepatology, Chinese Medical Association. Guideline on the management of cholestasis liver diseases (2021)[J]. Chinese Journal of Hepatology, 2022, 30(3): 253-263.] DOI: 10.3760/cma.j.cn112138-20211112-00795.

11.Wang Y, Wang Z, Gao M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial[J]. Liver Int, 2019, 39(11): 2102-2111. DOI: 10.1111/liv.14204.

12.司瑞丽, 周永芳, 刘宗展. 卡瑞利珠单抗致严重肝损伤一例分析[J]. 临床药物治疗杂志, 2022, 20(2): 91-92. [Si RL, Zhou YF, Liu ZZ, et al. Analysis of severe liver injury caused by camrelizumab: a case report[J]. Clinical Medication Journal, 2022, 20(2): 91-92.] DOI: 10.3969/j.issn.1672-3384.2022.02.016.

13.李梦娇, 梁平, 单彬, 等. 卡瑞利珠单抗致免疫相关性多器官损伤一例[J]. 临床药物治疗杂志, 2023, 21(4): 85-88. [Li MJ, Liang P, Shan B, et al. Immune-related multiple organ dysfunction induced by camrelizumab treatment: a case report[J]. Clinical Medication Journal, 2023, 21(4): 85-88.] DOI: 10.3969/j.issn.1672-3384.2023.04.018.

14.邢晓敏, 韩冰, 王凯. 卡瑞利珠单抗致致命性急性肝衰竭1例并文献分析[J]. 中南药学, 2023, 21(8): 2252-2255. [Xing XM, Han B, Wang K, et al. Carrilizumab induced fatal acute liver failure: a case report and literature analysis[J]. Central South Pharmacy, 2023, 21(8): 2252-2255.] DOI: 10.7539/j.issn.1672- 2981.2023.08.052.

15.Tan YW, Ye Y, Chen L. Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: a case report and literature review[J]. Open Med (Wars), 2021, 16(1): 553-557. DOI: 10.1515/med-2021-0267.

16.Patrinely JR, Mcguigan B, Chandra S, et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors[J]. Oncoimmunology, 2021, 10(1): 1875639. DOI: 10.1080/2162402X.2021.1875639.

17.Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury[J]. Esmo Open, 2017, 2(4): e000268. DOI: 10.1136/esmoopen-2017-000268.

18.Tan YW, Chen L, Zhou XB. Efficacy of artificial liver support system in severe immuneassociated hepatitis caused by camrelizumab: a case report and review of the literature[J]. World J Clin Cases, 2021, 9(17): 4415-4422. DOI: 10.12998/wjcc.v9.i17.4415.

19.Chen G, Wu M, Wu B, et al. Effects of dual plasma molecular adsorption system on liver function, electrolytes, inflammation, and immunity in patients with chronic severe hepatitis[J]. J Clin Lab Anal, 2019, 33(7): e22926. DOI: 10.1002/jcla.22926.

20.Shen Y, Wang XL, Wang B, et al. Survival benefits with artificial liver support system for acute-on-chronic liver failure[J]. Medicine, 2016, 95(3): e2506. DOI: 10.1097/MD. 0000000000002506.